HUTCHMED (China)CHIX:HCML 60 FCF Margin % is 1.24% as of Dec. 2025. GuruFocus rates CHIX:HCML with a GF Score™ of 60/100 and a GF Value™ of £2.24 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 963 Drug Manufacturers companies, HUTCHMED (China) ranks worse than 79.34% on this metric.
The historical rank and industry rank for HUTCHMED (China)'s FCF Margin % or its related term are showing as below:
CHIX:HCMl'
s FCF Margin % Range Over the Past 10 Years
Min: -71.59 Med: -17.25 Max: 22.27
Current: -16.07
During the past 13 years, the highest FCF Margin % of HUTCHMED (China) was 22.27%. The lowest was -71.59%. And the median was -17.25%.
CHIX:HCMl's FCF Margin % is ranked worse than 79.34% of 963
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs CHIX:HCMl: -16.07
HUTCHMED (China) FCF Margin % Related Terms
HUTCHMED (China) FCF Margin % Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:HCML vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s FCF Margin % distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (CHIX:HCML) has a FCF Margin % of 1.24% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #764 out of 963 companies in the Drug Manufacturers industry, placing it in the top 79.3%.
Is HUTCHMED (China)'s FCF Margin % too high?
HUTCHMED (China)'s current FCF Margin % is 1.24%. The Drug Manufacturers industry median FCF Margin % is 2.51. HUTCHMED (China)'s value of 1.24% is 50.6% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #764 out of 963 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #764 out of 963 companies for FCF Margin %. This places HUTCHMED (China) in the lower half of its industry. The industry median FCF Margin % is 2.51. HUTCHMED (China)'s value of 1.24% is 50.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current FCF Margin % of 1.24% is 50.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current FCF Margin % is 1.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (CHIX:HCML) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.24, compared to a current price of £1.67 — trading 25.4% below its estimated fair value. The current FCF Margin % is 1.24% and 50.6% below the Drug Manufacturers industry median of 2.51. HUTCHMED (China)'s overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For HUTCHMED (China) (CHIX:HCML), the current FCF Margin % is 1.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (CHIX:HCML) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of £1.67 is trading 25.4% below its estimated GF Value™ of £2.24.
GuruFocus considers HUTCHMED (China) to be Modestly Undervalued.
Key valuation signals for CHIX:HCML:
FCF Margin %: 1.24%
GF Value™: £2.24 vs. price of £1.67 (25.4% below fair value)
Industry Position: 50.6% below the Drug Manufacturers median (#764 of 963)
No single metric tells the full story. See the CHIX:HCML stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
60GF Score
Get the complete analysis for CHIX:HCML
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:HCML has been successfully added to your 
